KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Current Deferred Revenue (2017 - 2025)

Elanco Animal Health's Current Deferred Revenue history spans 9 years, with the latest figure at $416.0 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 25.3% year-over-year to $416.0 million; the TTM value through Dec 2025 reached $416.0 million, up 25.3%, while the annual FY2025 figure was $416.0 million, 25.3% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $416.0 million at Elanco Animal Health, up from $376.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $416.0 million in Q4 2025 and bottomed at $284.0 million in Q2 2022.
  • The 5-year median for Current Deferred Revenue is $330.0 million (2021), against an average of $334.0 million.
  • The largest annual shift saw Current Deferred Revenue soared 84.76% in 2021 before it fell 10.27% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $319.0 million in 2021, then increased by 1.57% to $324.0 million in 2022, then grew by 13.27% to $367.0 million in 2023, then decreased by 9.54% to $332.0 million in 2024, then grew by 25.3% to $416.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELAN's Current Deferred Revenue are $416.0 million (Q4 2025), $376.0 million (Q3 2025), and $367.0 million (Q2 2025).